Effectiveness of pitavastatin, an HMG-CoA reductase inhibitor, on lipid and glucose metabolism in Japanese patients with type 2 diabetes

被引：0
|
作者：
Kawai, Toshihide
Tokui, Mikiya
Funae, Osamu
Meguro, Shu
Yamada, Satoru
Tabata, Mitsuhisa
Shimada, Akira
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A461 / A461
页数：1
相关论文
共 50 条
  • [31] Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Isaacsohn, J
    Hunninghake, D
    Schrott, H
    Dujovne, CA
    Knopp, R
    Weiss, SR
    Bays, H
    Crouse, JR
    Davidson, MH
    Keilson, LM
    McKenney, J
    Korenman, SG
    Dobs, AS
    Stein, E
    Krauss, RM
    Maccubbin, D
    Cho, M
    Plotkin, DJ
    Mitchel, YB
    CLINICAL CARDIOLOGY, 2003, 26 (01) : 18 - 24
  • [32] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase
    Fujino, H
    Saito, T
    Ogawa, S
    Kojima, J
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (10) : 1305 - 1311
  • [33] Risk of Diabetes in Patients Treated with HMG-CoA Reductase Inhibitors
    Wang, Hye Jin
    Cho, Yongin
    Choe, Eun Yeong
    Seo, Ji Won
    Lee, Yongho
    Yun, Yu Jung
    Kim, Gyuri
    Park, Sehee
    Bae, Jaehyun
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    DIABETES, 2014, 63 : A367 - A367
  • [34] Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
    Cho, Yongin
    Choe, EunYeong
    Lee, Yong-ho
    Seo, Ji Won
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (04): : 482 - 488
  • [35] Relation between Baseline Lipid Levels and Effectiveness of HMG-CoA Reductase Inhibitors in Patients with Hyperlipidemia
    伍卫
    周淑娴
    韦育林
    张燕
    王景峰
    张旭明
    SouthChinaJournalofCardiology, 2001, (01) : 13 - 16
  • [36] Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine
    Yang, BB
    Hounslow, NJ
    Sedman, AJ
    Forgue, ST
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04): : 356 - 360
  • [37] A new and efficient synthesis of the HMG-CoA reductase inhibitor pitavastatin (vol 90, pg 1069, 2007)
    Acemoglu, Murat
    Brodbeck, Andre
    Garcia, Angel
    Grimler, Dominique
    Hassel, Marc
    Riss, Bernhard
    Schreiber, Robert
    HELVETICA CHIMICA ACTA, 2007, 90 (07) : 1447 - 1447
  • [38] HMG-CoA reductase inhibitors prevent bone loss in patients with type 2 diabetes mellitus.
    Nakashima, A
    Nakashima, R
    Masaki, T
    Harada, S
    Yorioka, N
    DIABETES, 2003, 52 : A128 - A128
  • [39] Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients
    James B. Wetmore
    Jonathan D. Mahnken
    Purna Mukhopadhyay
    Qingjiang Hou
    Edward F. Ellerbeck
    Sally K. Rigler
    John A. Spertus
    Theresa I. Shireman
    Journal of General Internal Medicine, 2012, 27 : 1475 - 1483
  • [40] Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes
    Chaiyakunapruk, N
    Boudreau, D
    Ramsey, SD
    JOURNAL OF CARDIOVASCULAR RISK, 2001, 8 (03): : 127 - 132
12345